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N-methyl-D-aspartate receptors (NMDARs) are 
glycoproteins in the brain central to learning and 
memory. The effects of glycosylation on the structure 
and dynamics of NMDARs are largely unknown. In 
this work, we use extensive molecular dynamics 
simulations of GluN1 and GluN2B ligand binding 
domains (LBDs) of NMDARs to investigate these 
effects. Our simulations predict that intra-domain 
interactions involving the glycan attached to residue 
GluN1-N440 stabilize closed-clamshell conformations 
of the GluN1 LBD. The glycan on GluN2B-N688 
shows a similar, though weaker, effect. Based on these 
results, and assuming the transferability of the results 
of LBD simulations to the full receptor, we predict that 
glycans at GluN1-N440 might play a potentiator role in 
NMDARs. To validate this prediction, we perform 
electrophysiological analysis of full-length NMDARs 
with a glycosylation-preventing GluN1-N440Q 
mutation, and demonstrate an increase in the glycine 
EC50 value. Overall, our results suggest an 




N-methyl-D-aspartate receptors (NMDARs) are 
transmembrane ion channels expressed in the nervous 
system and other organs. Malfunction of NMDARs is 
implicated in the pathology of various disorders, 
including schizophrenia, epilepsy, intellectual 
disability and autism.1-4 Each NMDAR consists of four 
subunits: two GluN1 subunits, and two GluN2 or 
GluN3 subunits. A large number of variants of 
NMDARs exists in vivo, arising from combinations of 
subunit types (GluN2A-D, GluN3A-B) and splicing 
variants (eight variants for GluN1, two variants for 
GluN3A).1,2 
NMDARs, like most membrane proteins, are heavily 
glycosylated. At least 11 glycans are attached to 
GluN1, at least 4 glycans to GluN2A, and at least 7 
glycans to the GluN2B subunit.5-7 Most of the glycans 
in NMDARs seem to be high-mannose Man5GlcNAc2 
(Man5) glycans,8 though other type of glycans may 
also occur.5-7 Data on the amount of glycosylation of 
an NMDAR are partially contradictory, but imply that 
the sites are nearly a hundred percent occupied by 
glycans.7-12 Surprisingly, glycans attached to NMDARs 
have not received much attention in previous 
publications on the structure and function of 
NMDARs. 
The effect of site-specific glycosylation on the 
structure and dynamics of NMDARs has not been 
investigated, and the neurological and psychiatric 
implications of abnormal NMDAR glycosylation 
patterns are unknown.13 The removal of all glycans 
from NMDARs was reported to decrease EC50 for 
glutamate by a factor of 3.6±0.7,10 increase the 
dissociation constant for non-competitive antagonist 
MK801 by a factor of 4.4±1.4,9 and reduce the ratio of 
the steady-state current amplitudes induced by 50 μM 
and 1 mM NMDA by a factor of 1.3±0.1.13 Treatment 
of NMDARs with certain lectins (glycan-binding 
proteins) increases EC50 for NMDA by 61-88%.7 
Consequences of changes in the glycosylation state at 
specific sites on NMDAR properties, however, remain 
poorly investigated.13 While no correlation between the 
overall level of NMDAR glycosylation and 
schizophrenia has been found,12 one hundred 
glycosylation disorders are known, including disorders 
with neurological symptoms, such as psychomotor 
retardation, ataxia, and hypotonia.14 
NMDARs consist of relatively autonomous 
functional parts or domains, as demonstrated by 
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electrophysiological and pharmacological studies of 
chimeric NMDARs.15,16 The modular character of 
NMDARs has been widely used in the previous work 
on NMDARs, for example, in the reconstruction of 
atomistic structures of NMDARs in various functional 
states from cryoEM data17,18 and in computational 
studies of NMDARs.19-22 In this paper, we follow this 
approach and focus on the ligand-binding domains 
(LBDs) of the GluN1 and GluN2B subunits of 
NMDARs. These modules, 292 and 295 amino acid 
residues in size respectively, collectively comprise 
nearly one fourth of the full receptor (GluN1/GluN2B 
isoform) (Fig. 1). Each NMDAR includes two copies 
of each of these domains. Coagonists glycine or D-
serine bind to GluN1 LBD, and the agonist glutamate 
binds to GluN2B LBD. Binding (or unbinding) of 
agonists or coagonists is believed to result in a 
conformational change in the corresponding domain, 
namely clamshell-like closing (or opening) of the 
domain (Fig. 2).20,23-27 If three events occur 
simultaneously: (1) glycine or D-serine binds to GluN1 
LBD, (2) glutamate binds to GluN2 LBD, and (3) the 
magnesium ‘plug’ is released from the transmembrane 
domain (TMD) by an appropriately depolarized 
membrane voltage, then the ion channel pore opens 
and calcium cations enter the cell, triggering signal 
cascades responsible for synaptic plasticity.1 
Disruptions in D-serine and glycine binding to GluN1 
LBD have implications in schizophrenia.28,29 Our 
investigation of GluN1 and GluN2B LBDs of NMDAR 
could clarify the connection between the 
(de)glycosylation of the full NMDARs and their 
biomedically relevant properties. 
In this paper, we adopt a novel approach to studying 
the consequences of glycosylation of NMDARs, 
namely computer simulations at atomic resolution, 
followed by experimental verification. In the past, 




Fig. 1. (a) Ligand binding domains (LBD) of GluN1 (blue) and GluN2B 
(green) subunits are parts of an NMDA receptor (gray, blue and green; 
protein part only shown). Each NMDAR contains two GluN1 and two 
GluN2B LBDs. The overall architecture of NMDARs is annotated on the 
right: the amino terminal domain (ATD) and the LBD are extracellular 
parts, the transmembrane domain (TMD) is immersed into the lipid bilayer, 
and the carboxyl terminal domain (CTD, not resolved in X-ray structures) 
is a cytosolic part. (b) For computational feasibility, this work focuses on 
the independent GluN1 LBD and GluN2B LBD. (c) Three Man5 glycans 
(red) were attached to GluN1 LBD and three Man5 glycans to GluN2B 
LBD to match the glycosylation pattern of NMDARs in the brain. 
Fig. 2. (a-b) The physiologically most important conformational changes in 
the GluN1 (a) and GluN2B (b) LBDs are believed to be clamshell-like 
opening/closing motions, which can be quantified, for example, by changes 
in the distance d between Cα atoms in residues 507 and 701 in GluN1 or 
residues 503 and 701 in GluN2B (gray, van-der-Waals spheres). Protein is 
shown in cartoon representation; glycans, van-der-Waals spheres. (c) 
Glycosylation stabilizes closed conformations of the GluN1 LBD, though 
open conformations are still populated. (P.d.f.: probability distribution 
function.) (d) A cartoon representation of the clamshell-like 
opening/closing motion in LBDs, with open conformations corresponding 
to larger values of d in panels (c,e). (e) Glycosylation of the GluN2B LBD 
stabilizes closed-clamshell conformations as well, though this effect is less 
pronounced as in GluN1 LBD. 
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role in the understanding of folding and conformational 
transitions in polypeptides and small proteins.30 
Simulating proteins with ~200-300 amino acid residues 
on biologically relevant timescales (up to ms) has 
recently become possible due to increases in 
computational power.31,32. The present work differs 
from previous simulations of NMDARs or their parts19-
21,33-37 in that the simulated systems include glycans, 
and the aggregate duration of molecular dynamics 
(MD) trajectories (0.6 milliseconds) exceeds that in the 
previous works by at least two orders of magnitude, 
closing the gap between the physiologically relevant 
and simulated timescales Quantitative statistical 
analysis based on Markov state models (MSMs) allows 
us to deduce equilibrium properties of the modeled 
systems from finite-length MD trajectories. Finally, 
our key prediction following from the simulations, 
namely the potentiator role of specific glycans on 
NMDARs, is corroborated by voltage-clamp 
electrophysiology experiments on wild-type and 
mutant full-length NMDARs. 
 
RESULTS 
Glycosylation stabilizes closed-clamshell 
conformations of GluN1 LBD and GluN2B LBD. 
Our simulations predict that both glycosylated and 
non-glycosylated GluN1 LBDs populate a wide 
spectrum of conformations at equilibrium, ranging 
from far open to far closed ones (Fig. 2). This result 
suggests that the available X-ray structures of GluN1 
LBD may not be capturing the full variety of 
conformations possible for the GluN1 LBD. Recently, 
cryoEM studies of NMDARs revealed several distinct 
conformations corresponding to the same functional 
state (agonist-bound non-active17 and agonist-and-
antagonist-bound18). Our results demonstrate, however, 
that a small number of discrete conformations (as four 
and six in the two cited papers, respectively) may be 
insufficient for a faithful representation of the 
conformational heterogeneity of NMDARs under 
physiological conditions. 
As for the changes incurred by glycosylation, we 
have found that the glycosylated GluN1 LBD tends to 
more frequently visit closed states at equilibrium, 
though open states are also accessible. Non-
glycosylated GluN1 LBD does not demonstrate this 
preference and populates open and closed 
conformations to a near-equal extent (Fig. 2c). 
Bootstrapping38 demonstrates that the conformations 
with the interlobe distance d in the range of 3.6 to 3.8 
nm are statistically significantly more populated, and 
those with d in the range of 4.6 to 4.8 nm are 
significantly less populated in glycosylated GluN1 
LBD in comparison to non-glycosylated GluN1 LBD 
(percentile bootstrap, confidence level of 95%, see 
section S3; for the exact definition of d, see Fig. 2a and 
section S5). 
Glycine binding promotes the closing of the GluN1 
LBD.18,20,23 Our simulations show that the effect of 
glycosylation is similar to the effect of coagonist 
binding. However, glycosylation alone, in the absence 
of glycine, is insufficient to change the population of 
closed forms of GluN1 LBD to 100%. We predict that 
glycosylation potentiates the closure of GluN1 LBD by 
a coagonist. The effect of glycosylation on the 
structure of LBDs is difficult to deduce from currently 
available experimental structures of GluN1 LBD, 
because most of the X-ray structures refer to non-
glycosylated proteins, while only three39,40 refer to 
partially glycosylated proteins and do not fully resolve 
the glycans. MD simulations provide a detailed 
dynamic model of glycans in GluN1 LBD. 
The results for the GluN2B simulations mirror the 
results for the GluN1 monomer, albeit to a more 
modest but significant degree. Despite starting from 
just one structure (mainly based on PDB entry 4PE5; 
see more details in section S5), the GluN2B LBD 
populates a wide distribution of conformations.  
Furthermore, our GluN2B simulations show that 
glycosylation results in a distribution of conformations 
that are skewed more toward closed-like states when 
compared with the non-glycosylated form (Fig. 2e). 
The difference between the probability distribution 
functions is significant in the ranges of the interlobe 
distances of 3.6 to 3.9 nm, where the glycosylated form 
is more stable, and 4.1 to 4.7 nm, where the non-
glycosylated form is more stable (percentile bootstrap, 
confidence level of 95%, see section S3). These results 
further our observations that glycosylation leads the 
LBDs to a more closed conformation, which may 
affect the activity of the ion channel. 
 
Simulations predict a mechanism of the 
potentiating effect of glycosylation. In closed 
conformations, the Man5 moiety at residue GluN1-
N440 (located in the disordered region between β-
sheets 3 and 4, in the terminology of ref. 23) in the 
lobe S1 of the GluN1 LBD can approach the lobe S2 of 
GluN1 LBD in the region of residues 710 to 723 (helix 
H and the disordered region between helices G and H), 
allowing for noncovalent interactions between the two 
lobes (Fig. 3a). On the protein side, these interactions 
4 
 
involve terminal oxygen atoms from the side chains of 
residues Glu712, Glu716, Gln719 and/or Asp723. On 
the side of the glycan, most OH groups from Man5 can 
transiently participate in the interactions, resulting in 
numerous conformations of the formed complex, 
without a single preferred structure (Fig. 3c). Though 
we have not performed simulations of GluN1 LBD 
with glycans other than Man5 due to the high 
computational cost of such simulations, the nonspecific 
involvement of the hydroxyl groups from the Man5 
glycan in the interlobe interactions suggests that other 
glycan types on residue N440 in the GluN1 LBD may 




In open conformations, Man5 and the lobe S2 of 
glycosylated GluN1 LBD are too far from each other to 
interact (Fig. 3b). This conclusion is evident from the 
analysis of the two-dimensional distribution between 
(1) the distance d between Cα atoms in residues 507 
and 701, quantifying how open or closed a current 
conformation of GluN1 LBD is (Fig. 2a), and (2) the 
distance dg-ol, defined as the shortest distance between 
heavy atoms in the glycan attached to N440 and heavy 
atoms in the other lobe of the protein (residues 710 to 
723), quantifying whether the glycan interacts with the 
other lobe of the protein or not. This two-dimensional 
distribution across all 536,651 snapshots in all 262 MD 
trajectories of glycosylated GluN1 LBD is shown in 
Fig. 4. The empty field in the lower right part of the 
plot shows that the interactions between the glycan and  
 
the lobe S2 do not occur in all open-clamshell 
conformations sampled in our simulations. 
Similar interactions were seen in simulations of the 
GluN2B LBD, with some notable differences. The 
GluN2B-N688 glycan is bound to the beginning of 
helix F, close to the hinge between the lobes S1 and S2 
of the GluN2B LBD and close to where glutamate 
binds. The glycan at this position is seen to interact 
extensively with residues on Loop 2, β-sheet 6, and 
helix D. Specifically, it appears that the hydroxyls of 
the glycan interact with residues Glu518, Lys488, 
Lys489, His486, Trp494, Glu517, and Arg519 (from 
most heavily engaged to least). However, unlike in 
GluN1, it appears the other two glycans may also 
potentiate closure of the clamshell. The glycan at 
GluN2B-N444, located between β-sheets 3 and 4, also 
interacts with the lobe S2 at the start of helix H, in 
particular with residues Arg712, Asp715, Asp716. 
These residues are similar to those we have found in 
GluN1. Further, the GluN2B-N491 glycan is bound to 
Loop 2 between β-sheets 6 and 7, and while it does not 
interact significantly with the lobe S2, it is close 
enough to the GluN2B-N688 that they interact in 15% 
of the frames in our simulations. GluN2B-N444 also 











(c)    
   
 
Fig. 3. (a) Man5 glycan at residue GluN1-N440 (van-der-Waals spheres, 
right) and amino acid residues Glu712, Glu716, Gln719 and Asp723 from 
the other lobe of GluN1 LBD (green) transiently noncovalently interact, 
which explains why closed conformations of the GluN1 LBD are more 
stable in the glycosylated state. (b) In open conformations of the GluN1 
LBD, the Man5 glycan and the other lobe of the glycoprotein do not 
interact. (c) Representative structures for the transient interactions between 
Man5 glycan (CPK representation) and residues 712, 716, 719, 723 (van-
der-Waals spheres) illustrate that no single stable structure exists under 
physiological conditions. 
Fig. 4. Glycan attached to GluN1-N440 interacts with the opposite lobe of 
the protein only in closed-clamshell conformations of GluN1 LBD. This 
heatmap shows a two-dimensional distribution of geometries of 
glycosylated GluN1 LBD in all 536,651 frames of 262 MD trajectories in 
terms of two variables: d, measuring whether a conformation is clamshell 
open/closed, and dg-ol, the shortest distance between heavy atoms in the 
glycan attached to N440 and heavy atoms in the other lobe of the protein 
(residues 710 to 723). (Note the log scales on the y axis and the colorbar). 
The empty field in the region of the diagram with d > 5.2 nm and dg-ol  < 0.5 
nm implies that no open-clamshell conformations with the glycan 
interacting with the opposite lobe of the protein have been reached. 
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frames (data not shown). Therefore, it appears that all 
of the glycans on GluN2B LBD could also potentiate 
closure, with GluN2B-N688 likely being the most 
influential. 
In our simulations, GluN2B does not sample open 
conformations as widely as those seen in the GluN1 
domain. This may be due to the fact that the GluN2B 
simulations have started from a single closed 
conformation and have yet to explore those fully open 
conformations. However, in contrast to the GluN1 
glycans, which are linked to the protein at residues far 
away from the opposite lobe, two of the GluN2B 
glycans (N491, N688) are linked to residues that are 




Method used for 
estimate 







MSM, 99 clusters, 
lag 256 ns 0.52 0.53 0.99 
MSM, 6 clusters, 
lag 256 ns 0.49 0.50 0.99 
MSM, 99 clusters, 
lag 128 ns 0.40 0.38 1.04 
tICA 0.42 0.43 0.98 
GluN2B LBD 
MSM, 99 clusters, 
lag 256 ns 0.21 0.19 1.14 
MSM, 6 clusters, 
lag 256 ns 0.16 0.17 1.11 
MSM, 99 clusters, 
lag 128 ns 0.13 0.12 1.08 
tICA 0.18 0.18 1.00 
 
 
Kinetics of clamshell-like opening and closing of 
GluN1 and GluN2B LBDs.  
GluN1 and GluN2B LBD opening/closing, 
according to our simulations, are fast and occur on the 
sub-microsecond timescales. To quantitatively 
determine the timescales from our MD trajectories, we 
used Markov state models (MSMs), an approach 
successfully applied in the past to other biomolecular 
systems.30-32 For the glycosylated form, the MSM with 
the optimal number of clusters (99 clusters, see section 
S1) predicts the slowest timescales of the 
opening/closing motion to be 0.5 and 0.2 μs in the 
GluN1 and GluN2B subunits, respectively, and some 
other plausible models yield comparable timescales 
(Table 1). The slowest timescales reported in Table 1 
are aggregate characteristics of complex transitions 
between a continuous spectrum of more open and more 
closed conformations of the LBDs. To a first 
approximation, the slowest timescale is comparable, by 
an order of magnitude, to the typical timescale of 
opening the clamshell of the LBD, as well as the 
typical timescale of its closing (see section S4). With 
the available amount of sampling, we have not found 
any significant difference in the timescale of 
opening/closing transitions in glycosylated and non-
glycosylated LBDs (Table 1). To the best of our 
knowledge, no experimental data on NMDAR LBDs 
opening/closing on the sub-microsecond timescale 
have been published so far. The results on GluN1 LBD 
dynamics obtained by single molecule fluorescence 
resonance energy transfer (smFRET)41-43 refer to 
millisecond timescales, and hence they can not be 
compared to the results of our simulations that make 
predictions on the microsecond timescale. No similar 
data on GluN2B LBD dynamics, to the best of our 
knowledge, have been published. 
Opening and closing of NMDARs as ion channels 
occur mainly on the timescales of 0.1 to 100 ms,44 two 
to five orders of magnitude slower than the timescales 
of clamshell-like opening and closing of LBDs that we 
predict in this work. Therefore, there should be no 
direct mechanical coupling between each event of a 
conformational change in LBDs, and opening or 
closing of the ion channel pore. Instead, the functional 
state of the full receptor (open ion channel, closed ion 
channel, etc.) must be controlled by changes in time-
averaged populations of various functional states of 
LBDs (open-clamshell vs. closed-clamshell). 
Discussion of mechanisms of interactions between 
GluN1 and GluN2B LBDs and the other parts of 
NMDARs33,34 goes beyond the scope of this work. 
Table 1. Timescale of the opening/closing transition in the 
glycosylated GluN1 LBD and GluN2B LBD are on the 
order of 0.5 and 0.2 μs, respectively. Surprisingly, adding 
glycans to GluN1 and GluN2B LBDs does not affect the 
rate of opening/closing, unlike the relative stability of the 
open-clamshell and closed-clamshell conformations. 
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Experimental validation of the potentiating role of 
glycans at GluN1 LBD in full-length NMDARs. Our 
molecular dynamics simulations suggest that 
glycosylation on GluN1-N440 stabilizes the activated 
(closed clamshell) structural state of the GluN1 LBD. 
This stabilization might enhance the ability of glycine 
to bind to the GluN1 LBD. Therefore, selective 
deglycosylation of GluN1-N440 might be expected to 
increase the EC50 for glycine. In order to test this 
prediction, we introduced the mutation N440Q into 
GluN1 by site-directed mutagenesis, which is a 
standard technique to completely prevent attachment of 
the N-linked glycan to this residue.7,13 We expressed 
wild-type (WT) and mutated full-length NMDARs in 
Xenopus oocytes and measured the glycine EC50 in 
voltage-clamp electrophysiology experiments (Fig. 
5a,b). Normalized dose-response curves were fitted 
using a standard Hill function (Fig. 5c).  
Whereas WT GluN2A-GluN1 channels were found 
to have glycine EC50 = 2.28 ± 0.03 μM, mutant 
GluN2A-GluN1 (N440Q) channels have glycine EC50 




increase in the glycine EC50 (p < 0.01, Student’s t-
test). Thus, while the glycan attached to GluN1-N440 
does not open NMDAR channels directly, it enhances 
the ability of glycine to activate the channels (in the 
presence of glutamate). 
Since glycine is an amino acid naturally present in 
vivo, the possibility of background glycine 
contamination should be taken into account. In our 
Xenopus oocyte assays, this contamination was 
negligible. We did not observe any current in the 
absence of glycine even at saturating glutamate 
concentrations. At the glycine concentration of 300 nM 
we observed noticeable NMDAR currents, indicating 
that the concentration of contaminating glycine, if 
present, must have been lower than 300 nM. Possible 
trace amounts of contaminating glycine (on the order 
of 100 nM) should have been present to the same 
extent in the case of both WT and mutated NMDARs 
experiments, and therefore could not account for the 
shift in the glycine EC50 that we observed. 
 
DISCUSSION 
Our work for the first time puts forward a hypothesis 
about the physiological role of specific glycans on 
NMDARs, specifically glycans at GluN1 N440 and 
GluN2B N688 residues, and supports it with 
experimental data. We find that intramolecular 
interactions involving glycans at the above-mentioned 
residues affect the conformations of the corresponding 
LBDs similarly to binding agonists, stabilizing closed-
clamshell conformations of the LBDs. This suggests 
that the glycans at GluN1-N440 and GluN2B-N688 
play intramolecular potentiator roles in NMDARs. 
The novelty of the present work is in the use of 
computational modeling to address the consequences 
of abnormal NMDAR glycosylation. The advantages 
of the computational approach include a unique degree 
of control over the model of the system under 
investigation and its detailed description on the atomic 
resolution level. In particular, we set up simulations 
such that they refer to physiological conditions 
(temperature of 310 K, water solution with the 
physiological salt concentration, primary structure 
exactly as in the human NMDARs, no interactions 
between different copies of glycoproteins, and the 
glycosylation pattern as in vivo). We recorded 
coordinates of each atom in the system every 0.2 ns. 
Though the computational approach provides a model-
dependent information about the system and cannot 
replace experiments, it can yield models with detailed 
structural information about the system under 
Fig. 5. The mutation GluN1-N440Q in the GluN1/GluN2A NMDA 
receptor results in a small but detectible rightward shift in the glycine 
EC50. (a,b) The wild-type and N-to-Q mutant channels were expressed in 
oocytes and the dose response was measured using two-electrode voltage 
clamp recordings.  (c) Averaged data from n = 12 recordings of each were 
plotted and fit with a Hill function to reveal a 50% increase in the glycine 
EC50 in the presence of the N440Q mutation, which makes glycosylation 
at this residue impossible. 
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investigation under physiological conditions that can 
rationally guide further experiments. 
On the other hand, computational modeling has 
certain limitations, including the size of systems that 
can be studied, the timescales of captured processes, 
and distortions introduced by employed models. We 
had to limit the size of the simulated system to GluN1 
or GluN2B LBDs of NMDAR. This approximation is 
justified by the experimentally established modular 
nature of NMDARs.15,16 Nevertheless, expanding 
simulations to full NMDARs and complexes of 
NMDARs with other proteins is desired in the future, 
but would be an immense computational undertaking 
(with up-to-date computational facilities, it would take 
~5 years to carry out similar simulations for the full 
NMDAR). Our simulations revealed dynamic 
processes in the GluN1 and GluN2B LBDs on the 
timescales below 1 μs. For comparison, Markov state 
models typically capture timescales comparable to the 
aggregate duration of all used MD trajectories (in this 
work, 0.1 – 0.3 ms for each system). Therefore, any 
processes on the timescale of ~1-100 μs are unlikely to 
occur in our simulations of GluN1 and GluN2B LBDs. 
This work does not attempt to address dynamics on the 
millisecond and longer timescales.41-43 Finally, the 
degree of uncertainty introduced by the use of specific 
models can be estimated from Table 1, which shows 
that the timescales of opening/closing in GluN1 and 
GluN2B LBDs predicted by several models are 
qualitatively the same. 
We experimentally confirmed the potentiating role 
of the glycan attached to GluN1-N440, predicted from 
our computations, by measuring changes in glycine 
EC50 after glycan removal using the GluN1-N440Q 
point mutation in the full receptor. Though our 
prediction on the role of this glycan was made based 
on computer simulations of a separate GluN1 LBD, 
and in principle could appear to be not transferable to 
the full receptor, the experimental validation was 
performed for the full-length NMDAR, demonstrating 
the transferability of the potentiating role of the glycan. 
Our observation that the glycine EC50 increases by 
approximately 50% is consistent with the idea that the 
N440 glycan stabilizes the glycine-bound state of 
GluN1 in the wild-type NMDA receptor. To estimate 
the scale of possible biomedical implications of such a 
change in the glycine EC50, consider the following 
data. Mutation L812M in the GluN2A subunit changes 
the glycine EC50 by a factor of 3.6 (in the receptor 
with one wild-type and one mutated GluN2A subunits) 
or 12 (with both GluN2A subunits mutated), and the 
glutamate EC50 by 4 and 10, respectively. A patient 
with this mutation had profound global developmental 
delay with no attainment of any milestones since 
birth.45  Mutation V667I in GluN2D changes EC50 for 
glycine and glutamate by factors of 1.7 and 1.5, 
respectively. This mutation was found in patients with 
epileptic encephalopathy and global developmental 
delay.46 Mutations G815R and F817L in GluN1 change 
EC50 for glutamate by factors of 4.4 and 4.2, 
respectively (data for glycine not reported). The 
phenotypes included severe intellectual disability, 
movement disorder, seizures.47 Multiple experimental 
data show that the coagonist binding sites on 
NMDARs are not 100% saturated in vivo, at least in 
some important locations in the brain (e.g., in 
hippocampus or prefrontal cortex),48-50 therefore, 
changes in the coagonist EC50 may lead to dramatic 
changes in the NMDA-dependent currents. Thus, it is 
not unreasonable to expect that the change in the 
glycine EC50 by a factor of 1.5 that we report might 
lead to neurological disorders, though maybe less 
severe than those listed above. 
Most structural studies of NMDARs (or their 
fragments) investigate the glycan-free forms.20,23-27 The 
absence of glycans in the GluN1 LBD structures in the 
cited works was possibly a side effect of using E. coli 
as the expression system. Likewise, past publications 
that undertook computational modeling of NMDARs 
or their parts19-22,33-37 have also omitted glycans. 
However, the absence or presence of glycans may 
significantly change functionally relevant 
conformations, as our results on Man5 at GluN1-N440 
and GluN2B-N688 suggest. 
We also make a number of testable predictions in 
this paper, in addition to the change in glycine affinity 
mentioned above, namely: 
1) The clamshell-like opening/closing motions of 
GluN1 and GluN2B LBDs occur on a sub-microsecond 
timescale, which could be checked, for example, by T-
jump IR spectroscopy or electron paramagnetic 
resonance (EPR). The previous literature does not 
seem to be consistent on the timescale of these 
motions. On the one hand, no significant free energy 
barrier between the clamshell-open and closed states 
was found in previous simulations of GluN1 LBD.20 
On the other hand, the opening/closing motion was 
reported to occur on the millisecond timescale, as 
determined by smFRET, a method with millisecond 
temporal resolution.41-43 Our prediction suggests using 
sub-microsecond-resolution methods to investigate the 
opening/closing motion of GluN1 and GluN2B LBDs 
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such that it is decoupled from other conformational 
transitions that may occur in GluN1 and GluN2B 
LBDs on the millisecond timescale. 
2) The equilibrium concentrations of clamshell-
closed conformations after glycosylating (de-
glycosylating) residue N440 in the separate GluN1 
LBD module and, presumably, in the full NMDAR, 
increase (decrease, respectively); the same for 
(de)glycosylation at residue N688 in GluN2B subunit. 
3) The changes in the equilibrium concentrations of 
clamshell-closed conformations of GluN1 LBD are 
disrupted by mutations in the residues involved in the 
transient interactions with Man5 glycan at N440 
(Glu712, Glu716, Gln719 and Asp723 in GluN1 
subunit). Because of the non-specific character of 
interactions between the glycan and these four amino 
acid residues, mutations in all (or maybe most) of them 
are required for a noticeable effect on the relative 
stability of the GluN1 LBD conformations. 
All these predictions, to the best of our knowledge, 
have not been experimentally tested so far. 
The identification of NMDAR glycosylation as 
important for agonist affinity could have potential 
medical consequences if glycosylation were 
differentially regulated under physiological and 
pathological situations. As NMDAR dysfunction is 
implicated in diseases including autism, epilepsy and 
schizophrenia, our work suggests that future studies 
could look for abnormal NMDAR glycosylation, 
especially at GluN1 N440 and GluN2B N688 residues, 
in the studies of various neurological disorders. 
 
METHODS 
Molecular dynamics simulations. We ran all-atom MD 
simulations of glycosylated and non-glycosylated GluN1 LBDs 
(Fig. 1b-c) in explicit solvent under physiological conditions (310 
K, water solution with the ion strength of 0.154 M, amino acid 
sequence exactly as in the human NMDARs (uniprot code Q05586-
3), glycosylation with Man5 at residues 440, 471 and 771). 
Simulations started from 23 different geometries corresponding to 
different functional states of the GluN1 LBD. In total, 262 and 196 
MD trajectories with the aggregate simulation time of 0.107 ms and 
0.106 ms were generated for the glycosylated and non-glycosylated 
GluN1 LBDs, respectively. We followed up these simulations with 
similar ones on GluN2B LBD. The GluN2B subunit is known to be 
glycosylated at residues 444, 491, and 688. All-atom simulations of 
the glycosylated and non-glycosylated forms of GluN2B were 
performed using a model built from the full channel structures. This 
resulted in 247 and 613 trajectories totaling 0.086 and 0.344 
milliseconds for the glycosylated and non-glycoslated forms, 
respectively. For more details, see section S5. 
 
Interpretation of molecular dynamics trajectories. Markov state 
models30 were built to reconstruct the thermodynamic and kinetic 
properties of the NPT ensembles of glycosylated and non-
glycosylated GluN1 LBD and GluN2B LBD proteins at 
equilibrium from finite-length MD trajectories, each of which did 
not completely sample the configuration space. Markov state 
models with 99 clusters and the lag time of 256 ns were used [see 
Supplementary Information (SI), sections S1 and S2]. For more 
details, see section S5. 
 
Glycine EC50 measurements.  Expression of NMDAR channels 
in Xenopus oocytes was achieved by subcloning the human cDNAs 
for these channels into the pTNT vector (Clontech). We expressed 
GluN1 paired with GluN2A, which provides rapid and efficient 
expression of the full-length NDMARs in Xenopus oocytes.  
Mutagenesis was carried out using the Quikchange Lightning Multi 
kit (Agilent) as per manufacturer’s instructions.  To produce RNA 
for injection into oocytes, the constructs were linearized, purified, 
and used as the substrate for T7 RNA polymerase-mediated RNA 
synthesis (mMessage mMachine T7, Ambion).  Oocytes were de-
folliculated with 2 mg/ml collagenase type 2 in OR-2 solution (in 
mM: 82.5 NaCl, 2.4 KCl, 1 MgCl2 and 5 HEPES), and then 
transferred to ND-96 solution (in mM: 96 NaCl, 2 KCl, 1 MgCl2, 
1.8 CaCl2 and 5 HEPES). The N440Q mutant GluN2A-GluN1 
channels expressed at similar levels as wild-type GluN2A-GluN1 
channels.  For two-electrode voltage-clamp (TEVC) recordings, 
oocytes were injected with mRNA for hGluN1-1a and hGluN2A, 
using either WT or mutant mRNA. Glycine dose response 
experiments were performed by perfusing increasing 
concentrations of glycine (from 0.1 PM to 100 PM) onto the 
oocytes (all solutions contained 100 PM glutamate to allow 
glycine-dependent NMDAR activation).  Measurements were made 
on both wild-type and mutant channels in side-by-side recordings 
to reduce variability. The N-to-Q mutation is a common technique 
used to prevent glycosylation of proteins at specific positions. It has 
previously been successfully applied to NMDARs.7,13 We have not 
been able to make measurements of EC50 for the NMDAR with 
mutation GluN2B-N688Q, because the protein with this mutation 
did not express for unknown reasons. 
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SUPPLEMENTARY INFORMATION
Section S1. Choice of the optimal number of Markov states
The optimal number of Markov states in the Markov state model of the glycosylated GluN1 LBD
was chosen by cross-validation with the use of generalized matrix Rayleigh quotient (GMRQ)1
for the slowest implicit timescale as the score function. 25 various random divisions of the
dataset of all MD trajectories for glycosylated GluN1 LBD into a training set (80% of
trajectories) and a test set (20% of trajectories) were performed. Markov state models with the
number of Markov states ranging from 2 to 1000 were built from each training set, and then the
performance of each MSM was scored against the corresponding test set. Scores averaged over
25 various divisions are reported in Fig. S1a. As expected, the average score for training sets
increases with the increase of the number of states, while the average score for test sets reaches a
maximum value and decreases with the further increase of the number of states because of
overfitting. The optimal number of states corresponding to the maximum average test score turns
out to be 99. As for the glycosylated GluN2B LBD, a similar procedure leads to the optimum
number of Markov states maximizing the average test score to be 118 (Fig. S1b). In both cases,
the score is not very sensitive to the number of states in the vicinities of the extrema, allowing us
to expect reasonable performance of Markov models in a wide range of the numbers of Markov
states, from ~50 to ~500. Taking this lack of sensitivity into account, we used the same number
of Markov states, namely 99, to model all four molecular systems under investigation,
glycosylated and non-glycosylated GluN1 and GluN2B LBDs, to ensure the comparability of the
results for glycosylated and non-glycosylated forms, as well as different subunits.
2Fig. S1. (a) Cross-validation with the use of generalized matrix Rayleigh quotient (GMRQ) for
the slowest implicit timescale as the score function was used to choose the optimal number of
Markov states to model glycosylated GluN1 LBD, namely 99. Average scores for training sets
(red) and test sets (blue) over 25 random divisions of the data set into training and test sets are
provided. (b) In the case of our glycosylated GluN2B LBD simulations, the optimal number of
Markov states appears to be 118, though the model with 99 states is relatively good, too. For
comparison, we used Markov models with 99 states both for GluN1 and GluN2B LBDs.
3Section S2. Choice of the optimal lag time
Lag time is the distance in time between neighboring frames from MD trajectories used to
estimate the MSM transition matrix. Too small values of the lag time can lead to inadequacy of
MSM due to a violation of the Markov assumption at short timescales. Too large values of the
lag time lead to poorer statistics on transitions. Analysis of the convergence of implicit
timescales of MSMs as a function of lag time (Fig. S2) can be used to choose the optimal value
of lag time. For our simulations of glycosylated GluN1 LBD, we chose the lag time of 256 ns. In
the case of GluN2B LBD, the overall picture is the same as in GluN1 LBD. For the purpose of
comparison, this lag time was used to model all four molecular systems under investigation,
glycosylated and non-glycosylated GluN1 and GluN2B LBDs.
(see next page)
4Fig. S2. (a) Five slowest implicit timescales, estimated from MSM for glycosylated GluN1 LBD
with 99 states, converge to stationary values as the lag time increases, confirming the
5applicability of the Markov assumption. We chose the lag time of 256 ns as a compromise
between ensuring Markov and good statistics on transitions between Markov states. Note the gap
between the first and the second slowest timescales by a factor of 2.5-4 (depending on the lag
time), implying a relatively good decoupling of clamshell opening/closing motion from other
conformational transitions in glycosylated GluN1 LBD. (b) In GluN2B LBD, the overall picture
with implicit timescales is the same. However, the timescales are faster (up to ~0.2 μs, vs. up to
~0.5 μs in GluN1), and the gap between the first and the second slowest timescales is smaller (a
factor of ~1.4-1.6).
Section S3. Estimate of the statistical significance of the difference between
probability distribution functions for glycosylated and non-glycosylated
GluN1 and GluN2B LBDs by bootstrapping
We performed 1000 rounds of resampling of time series d(t) for glycosylated, and, separately,
non-glycosylated GluN1 LBD. For each resampled data set, the probability distribution functions
for glycosylated and non-glycosylated GluN1 LBD, denoted below as f1(d) and f2(d),
respectively, were computed with the use of Markov state models with 99 states and the lag time
of 256 ns. Then, the difference between the two probability distributions, df(d) = f1(d) – f2(d),
was computed for each of 1000 sets of resampled data. Confidence intervals for df(d) were
computed at each d by percentile bootstrap of 1000 estimates of df(d). The values of d for which
the probability distribution functions for glycosylated GluN1 LBD statistically significantly
exceeds the probability distribution functions for non-glycosylated GluN1 LBD were determined
as those values of d at which the confidence intervals for df(d) are entirely above zero, and vice
versa. The confidence intervals for df(d) for the P-values of 95% and 99% are shown in Fig. S3a.
Similar computations were performed for GluN2B LBD (Fig. S3b).
(see next page)
6Fig. S3. (a) Conformations of GluN1 LBD with d in the range of 3.61 to 3.85 nm are statistically
significantly more populated (the confidence interval for df, which is the difference between
probability distribution functions for glycosylated and non-glycosylated GluN1 LBD, is above
zero at these values of d), and those with d in the range of 4.57 to 4.78 nm are statistically
significantly less populated (the confidence interval for df is below zero) in glycosylated GluN1
LBD than in non-glycosylated GluN1 LBD (percentile bootstrap, confidence level of 95%).
7Black: the best estimate of df based on the available MD trajectories (in other words, the red
curve from Fig. 2c minus the blue curve from Fig. 2c). Red: the confidence interval for df with
the confidence level of 95% estimated by percentile bootstrap. Blue: the same, with 99%
confidence level. (b) In GluN2B LBD, the glycosylated form is statistically significantly more
stable in the ranges of 3.55 to 3.95 nm, and less stable between 4.05 to 4.69 nm (percentile
bootstrap, confidence level of 95%).
Section S4. Physical interpretation of slowest timescales of Markov state
models
To clarify the meaning of the slowest Markov state model timescale, consider a simplified
physico-chemical two-state model of GluN1 or GluN2B LBD, with one open and one closed







and assume that the transitions between these two states are described by the first order reaction
kinetics, with the rate constants kcl and kop for closing and opening, respectively. Then the
concentration of the open and closed forms will depend on time t as follows:
       0 1 2 3, ,cl op cl opk k t k k tO c c e C c c e       (2)
where constants c0, c1, c2 and c3 are determined by the initial concentrations of the open and
closed forms and the ratio of the rate constants kcl / kop. On the other hand, the time evolution of
the ensemble of Markov processes for an n-state Markov chain can be written in comparable
notations as
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where i are characteristic timescales of the Markov chain sorted in the descending order,
1 2 1... .n      If the slowest characteristic timescale 1 is significantly greater than the other
characteristic timescales, then for sufficiently large t eq. (2) approximates eq. (3) with
1






where cl is the time over which half of all open conformations would close, provided that
closed conformations could not open, and op is the time over which half of all closed
conformations would open, provided that open conformations could not close. The equilibrium
concentrations of the open and closed forms of GluN1 or GluN2B LBDs are comparable by the
order of magnitude, as Fig. 2(c,e) shows. Therefore ,cl opk k and hence, 1 1, .cl op     Thus,
the slowest timescale reported in Table 1 is an aggregate characteristic of complex transitions
8between more open and more closed conformations of the GluN1 and GluN2B LBDs. In the first
approximation the slowest timescale is comparable, by the order of magnitude, to typical
timescales of both opening and closing the clamshell.
Section S5. Methods: more detailed description
Molecular dynamics simulations. Initial 23 geometries of GluN1 LBD were prepared based on
all experimental X-ray structures of GluN1 LBD available at the moment when our simulations
started (PDB codes: 1PB7, 1PB8, 1PB9, 1PBQ,2 1Y1M, 1Y1Z, 1Y20,3 2A5T,4 4KCC,5 4KFQ,6
4NF4, 4NF5, 4NF6, 4NF8,7 4PE5,8 4TLL, 4TLM9). The proteins consisted of residues 393 to
546 and 663 to 800 (residue numbering everywhere in this article corresponds to the full GluN1
sequence). The primary structure of GluN1 subunit from H. sapiens, isoform 3 (NR1-3), uniprot
identifier Q05586-1, was used. The structures were solvated in TIP3P water with sodium and
chloride ions in the amount corresponding to the physiological concentration of 0.154 M.
Glycosylation was performed with the use of Glycoprotein Builder.10 Energy minimization,
heating and two-stage preequilibration resulted in preequilibrated structures used for production
simulations. These preequilibrated structures were within 1 Å from the original X-ray structures
in terms of RMSD for the protein backbone atoms.
For the GluN2B simulations, a homology model of the LBD was built from full NMDAR
X-ray structures (PDB codes: 4PE5,8 4TLL, 4TLM9). The six LBD domains (two from each
structure) were aligned and used to build a consensus model using Schrodinger’s Maestro
software (version 2015-1).11 The template sequence consisted of residues 401 to 604 and 658 to
806, with a glycine linker between 604 and 658. The sequence was based off of the GluN2B
subunit from H. sapiens, uniprot identifier Q13224-1. The structures were solvated in TIP3P
water with sodium and chlorine ions added to neutralize the system. For the glycosylated system,
glycosylation was performed with the use of the Glycoprotein Builder.10
MD simulations were performed with Amber ff99SB-ILDN12 and GLYCAM_06i13 force
fields (for the protein and glycan parts, respectively), resulting in 262 MD trajectories for
glycosylated and 196 MD trajectories for non-glycosylated GluN1 LBD, with the aggregate
duration of 107 and 106 μs, respectively. For the GluN2B LBD, 247 trajectories for the
glycosylated and 613 trajectories for the glycosylated form were performed, resulting in an
aggregate simulation time of 86 and 344 μs, respectively. Simulations were run on
Folding@home and various types of GPUs available on Stanford computer clusters (Sherlock,
XStream). Depending on the type of the used GPU, some of the trajectories were generated in
OpenMM with hydrogen reweighting, constrained length of all covalent bonds and the timestep
of 5 fs,14 and other trajectories were run in Amber with hydrogen reweighting, constrained length
of covalent bonds with hydrogen atoms and the timestep of 4 fs.15 Coordinates of all atoms were
recorded every 0.2 ns. The following checks of the resulting trajectories were performed:
stability of the volume, potential and total energy of the system; the distance between mirror
images of the (glyco)protein created by periodic boundary conditions (in more than 80% of
frames exceeded 19 Å, 16 Å, 25 Å and 14 Å for the glycosylated GluN1 LBD, non-glycosylated
GluN1 LBD, glycosylated GluN2B LBD and non-glycosylated GluN2B LBD, respectively; in
more than 99% of frames, exceeded 15, 11, 16 and 9.5 Å, respectively); RMSD of the protein
backbones in neighboring frames in each MD trajectory (always stayed below 4.5 Å for the
9timestep of 0.2 ns, and typically equaled ~1.5 Å). Visual molecular dynamics (VMD) package16
was used to visualize molecular structures.
Interpretation of molecular dynamics trajectories. Markov state models17 were built to
reconstruct the thermodynamic and kinetic properties of the NPT ensembles of glycosylated and
non-glycosylated GluN1 LBD and GluN2B LBD proteins at equilibrium from finite-length MD
trajectories, each of which did not completely sample the configuration space. For featurization,
the distance d between Cα atoms in residues 507 and 701 in GluN1 LBD was used to capture the
opening/closing motion of the module. This choice of the residues followed that used in the
experimental papers on smFRET investigation of GluN1 LBD opening/closing dynamics on the
millisecond-to-second timescale.18,19 In GluN2B LBD, the distance between Cα atoms in residues
503 and 701, which are homologous to residues 507 and 701 in GluN1 subunit, was used. The
MSMbuilder 3.3 package20 was used to construct microstate models with varying number of
Markov states. Maximum Likelihood Estimator was used to generate a transition probability
matrix Tij, which maps out the probability of transitioning from state i at time t to state j at time
t  , where is the lag time of the model. The optimal number of Markov states was chosen by
cross-validation with the use of generalized matrix Rayleigh quotient (GMRQ) for the slowest
implicit timescale as the score function (SI, section S1).1 The Markov lag time was chosen to be
256 ns based on the analysis of the plots for the implied timescales versus lag times used to
compute these implied timescales (SI, section S2). MSM-weighted probability distributions were
obtained by binning the raw data within each MSM state and weighting it by the MSM
equilibrium state population. To estimate the stability of our key conclusions relative to the
model framework used to process the MD data, we also present the results for MSMs with a
different number of clusters or a different lag time, as well as the timescale estimated from time-
structure independent component analysis (tICA),21 all with the same featurization d (Table 1).
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